FDA Greenlights GSK's Blenrep for Blood Cancer Treatment in New Combo Therapy

The FDA has approved GSK plcs blood cancer drug, Blenrep, in a new combination therapy for multiple myeloma, marking its return after a three-year market withdrawal.

• The Food and Drug Administration approved Blenrep, also known as Belantamab mafodotin, in combination with bortezomib and dexamethasone for multiple myeloma patients.
• This approval targets patients whose multiple myeloma has relapsed or is resistant after at least one prior therapy, addressing a significant unmet need in the disease management.
• Blenreps return to the market follows rigorous phases of clinical research that demonstrated its efficacy when paired with established treatments like bortezomib and dexamethasone.